billS3934Event Thursday, February 26, 2026Analyzed

Medical Nutrition Therapy Act of 2026

Bullish
Impact4/10

Summary

The Medical Nutrition Therapy Act of 2026 (S.3934) has been introduced in the Senate, proposing to expand Medicare coverage for medical nutrition therapy to more conditions and allow additional healthcare professionals to provide referrals. This early-stage bill signals potential growth for healthcare providers and insurers involved in nutrition services, including companies like UnitedHealth Group, Centene, Humana, AMN Healthcare, and CVS Health.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S.3934 expands Medicare coverage for medical nutrition therapy to additional chronic conditions and allows more healthcare professionals to provide referrals.
  • 2.The bill is in an early stage, having been introduced in the Senate and referred to the Committee on Finance, with a related House bill from the previous session.
  • 3.Healthcare insurers and providers, particularly those with Medicare exposure or staffing services for nutrition professionals, stand to benefit from increased demand for covered services.

Market Implications

The Medical Nutrition Therapy Act of 2026, if enacted, would expand the addressable market for medical nutrition therapy services under Medicare. This directly benefits health insurance providers like UnitedHealth Group ($UNH), Centene Corporation ($CNC), and Humana Inc. ($HUM) by increasing the scope of covered services, potentially leading to higher claims volume and improved member health outcomes, which can positively influence their Medicare Advantage plan performance. Staffing companies such as AMN Healthcare Services ($AMN) could see increased demand for registered dietitians and other advanced practice providers. CVS Health ($CVS), with its Aetna insurance arm and retail health clinics, is also positioned to benefit from increased utilization of these services. The recent positive market performance of these tickers, with $UNH up +42.09%, $CNC up +52.16%, $HUM up +37.27%, $CVS up +15.84%, and $AMN up +12.59% over the last 30 days, suggests a broader bullish sentiment in the healthcare sector that this bill's potential passage could further support.

Full Analysis

The Medical Nutrition Therapy Act of 2026 (S.3934) was introduced in the Senate on February 26, 2026, and subsequently referred to the Committee on Finance. This bill aims to amend title XVIII of the Social Security Act to expand Medicare coverage for medical nutrition therapy services. Currently, Medicare covers these services only for individuals with diabetes or kidney disease, provided by a registered dietitian or nutrition professional with a physician referral. S.3934 proposes extending coverage to individuals with conditions such as obesity, eating disorders, cancer, and HIV/AIDS, and would allow physician assistants, nurse practitioners, clinical nurse specialists, and clinical psychologists (for eating disorders) to make referrals. This is an early-stage bill, with only two cosponsors, indicating it has just begun its legislative journey. This bill does not explicitly authorize or appropriate a specific funding amount. Instead, it expands the scope of services covered under the existing Medicare Part B program. The financial mechanism is an increase in the volume of reimbursable services under Medicare. This means that if the bill passes, the federal government would pay for more medical nutrition therapy services through the existing Medicare payment structures, rather than allocating new, dedicated funds. The impact would be an increase in the total expenditure on these services within the Medicare budget, funded by general revenues. Structural winners would be healthcare providers specializing in nutrition services, including registered dietitians and nutrition professionals, as well as the broader healthcare system that manages chronic conditions. Companies like UnitedHealth Group ($UNH), Centene Corporation ($CNC), and Humana Inc. ($HUM), which operate significant Medicare Advantage and Part B administrative services, would see an increase in claims processing and potentially improved health outcomes for their members, which can positively impact their business models. AMN Healthcare Services ($AMN) would likely see increased demand for staffing nutrition professionals. CVS Health ($CVS) could also benefit through its Aetna insurance arm and its retail health clinics. There are no clear structural losers identified by this bill, as it expands coverage rather than restricting it. Looking at recent market data, several potentially affected tickers have shown positive trends. UnitedHealth Group ($UNH) is up +4.11% in the last 7 days and +42.09% in the last 30 days, currently at $368.04. Centene Corporation ($CNC) has seen a significant increase of +25.07% in the last 7 days and +52.16% in the last 30 days, trading at $48.69. Humana Inc. ($HUM) is up +6.77% in the last 7 days and +37.27% in the last 30 days, at $232.11. CVS Health ($CVS) is up +6.21% in the last 7 days and +15.84% in the last 30 days, at $81.18. AMN Healthcare Services ($AMN) is up +1.82% in the last 7 days and +12.59% in the last 30 days, at $21.29. These positive movements across major healthcare players suggest a generally bullish sentiment in the sector, though these specific movements cannot be directly attributed solely to this early-stage bill. The bill's progression would likely contribute to this positive outlook for companies involved in Medicare services. For this bill to become law, it must pass the Senate Committee on Finance, then the full Senate, then the House of Representatives, and finally be signed by the President. Given its early stage and the current date of April 28, 2026, significant legislative steps remain. The existence of a related bill, HR6199 (Medical Nutrition Therapy Act of 2025), suggests bipartisan interest in the issue, which could aid its progression. However, the related bill is from the previous Congress session and has not advanced, indicating that similar legislation has faced challenges in the past. There are no direct presidential actions that amplify or conflict with this bill. The Presidential Memorandum on Accelerating Medical Treatments for Serious Mental Illness is related to mental health but does not directly address nutrition therapy coverage under Medicare.

Market Impact Score

4/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.